Skip to main content
NICE recommends new combo therapy for first multiple myeloma relapse
6/15/2017

The National Institute for Health Care Excellence has recommended Amgen's Kyprolis, or carfilzomib, for the treatment of relapsed multiple myeloma in patients who have not received Janssen's Velcade, or bortezomib. Progression-free survival averaged 18.7 months in study participants taking both Kyprolis and dexamethasone, compared with 9.4 months in patients taking Velcade and dexamethasone.

Full Story: